Vaxcyte Inc

Common Name

Vaxcyte

Country

United States

Sector

Healthcare

Industry

Biotechnology

Employees

414

Ticker

PCVX

Exchange

NASDAQ/NGS

Website

vaxcyte.com

Description

Vaxcyte Inc. is a biotechnology company focused on developing innovative vaccines for preventing infectious diseases. The primary objective of the company is to create safer and more effective vaccine... Show more

Income Statement Balance Sheet

Financial Statements of Vaxcyte

Below are the financial statements of Vaxcyte, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?

Learn More

All figures in millions of USD	2024 as of 2024-12-31	2023 as of 2023-12-31
Assets	—	—
Current assets	—	—
Cash and cash equivalents	387.88^a	397.45^a
Short-term investments	1,359.33^a	682.78^a
Prepaid expenses and other current assets	40.78^a	15.73^a
Total current assets	1,787.99^a	1,095.95^a
Property and equipment, net	198.05^a	79.63^a
Operating lease right-of-use assets	72.1^a	31^a
Long-term investments	1,387.51^a	162.68^a
Restricted cash	1.32^a	1.1^a
Other assets	64.36^a	37.56^a
Total noncurrent assets	1,723.33^a	311.96^a
Total assets	3,511.32^a	1,407.92^a
Liabilities and stockholders' equity	—	—
Current liabilities	—	—
Accounts payable	48.45^a	14.59^a
Accrued compensation	20.56^a	11.06^a
Accrued contract manufacturing expenses	36.16^a	52.77^a
Accrued expenses	29.12^a	59.82^a
Operating lease liabilities - current	5.89^a	7.11^a
Total current liabilities	140.18^a	145.34^a
Operating lease liabilities - long-term	65.22^a	22.11^a
Other liabilities	0.1^a	0^a
Total liabilities	205.5^a	167.45^a
Stockholders' equity	—	—
Preferred stock	0^a	0^a
Common stock	0.13^a	0.1^a
Additional paid-in capital	4,697.88^a	2,164.58^a
Accumulated other comprehensive income (loss)	-3.87^a	0.18^a
Accumulated deficit	-1,388.32^a	-924.39^a
Total stockholders' equity	3,305.82^a	1,240.47^a
Total liabilities and stockholders' equity	3,511.32^a	1,407.92^a

Download Data

Verified Sources Behind Vaxcyte’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Vaxcyte’s data sources below and access millions more through our Disclosure Search.

a. Vaxcyte's 10-K 2024

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

Vaxcyte Inc

Financial Statements of Vaxcyte

Verified Sources Behind Vaxcyte’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

BioMarin Pharmaceutical Inc

Denali Therapeutics Inc

Blueprint Medicines Corp

Dyne Therapeutics Inc

Apogee Therapeutics Inc

Cytokinetics Inc